Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q1 2016 · 10-Q
Revenue$1.26M$1.26M+21.0% vs Q1 2015 Net Income-$1.02M-$1.02MN/M vs Q1 2015 EPS Diluted-$0.02-$0.02N/M vs Q1 2015 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flow-$1,109,000N/M Free Cash Flowderived-$1,113,000N/M Margins · derivedGross margin6.6%+11.8 pt vs Q1 2015
Operating margin-86.5%+24.9 pt vs Q1 2015
Net margin-80.8%−5.4 pt vs Q1 2015
ended Sep 30, 2015 · filed Nov 9, 2015 · 40 d after period end